Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
Get Alerts TSHA Hot Sheet
Join SI Premium – FREE
20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 10:15 am ET
Chardan 5th Annual Manufacturing Summit on Monday, April 26, 2021 at 1:00 pm ET
DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats for the 20th Annual Needham Virtual Healthcare Conference and the Chardan 5th Annual Manufacturing Summit.
Conferences Details: |
||
Event: |
20th Annual Needham Virtual Healthcare Conference |
|
Date: |
Monday, April 12, 2021 |
|
Time: |
10:15 am ET |
|
Format: |
Fireside chat |
|
Participants: |
RA Session II, President, Founder and CEO |
|
|
|
|
Event: |
Chardan 5th Annual Manufacturing Summit |
|
Date: |
Monday, April 26, 2021 |
|
Time: |
1:00 pm ET |
|
Format: |
Fireside chat |
|
Participants: |
RA Session II, President, Founder and CEO |
|
|
Fred Porter, Ph.D., Chief Technical Officer |
|
|
Greg Gara, Senior Vice President of Manufacturing |
Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005218/en/
Company Contact:
Kimberly Lee, D.O.
SVP, Corporate Communications and Investor Relations
Taysha Gene Therapies
[email protected]
Media Contact:
Carolyn Hawley
Canale Communications
[email protected]
Source: Taysha Gene Therapies, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024
- Issue of Supplementary Prospectus
- Trilogy International Partners Inc. and SG Enterprises II, LLC Announce Completion of Go-Private Transaction
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Needham & Company, Chardan Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!